CRISPR Therapeutics AG (CRSP) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...

A CRISPR Therapy Just Cured A Disease From Inside The Body For The First Time. The Gene-Editing Era Officially Started Monday.

CRISPR Therapeutics (NasdaqGM:CRSP) is entering a second phase of its business as the CASGEVY commercial rollout gains ...

3 Biotech Stocks That Could Benefit from the Patent Cliff CRISPR Therapeutics (NASDAQ:CRSP) Chief Executive Officer Sam ...

A team of engineers at the University of Florida has developed a new form of CRISPR technology that could make diagnostics ...

When activated by its target, the newly characterized molecule rips the genome apart, a lethal move that researchers can ...

Intellia Therapeutics said its Crispr-based treatment for hereditary angioedema met its goals in a Phase 3 trial, marking a milestone for gene editing.

2023 was the year that CRISPR gene-editing sliced its way out of the lab and into the public consciousness—and American medical system. The Food and Drug Administration recently approved the first ...

Bullish sentiment for CRISPR Therapeutics makes sense given the potential catalysts ahead. The stock could soar if it ...

The biotech's candidate may treat a great number of illnesses that have one thing in common.

Banas is associate director of research at the Gene Editing Institute at ChristianaCare, where Kmiec is founder and executive director. The medical promise of CRISPR gene editing can be seen most ...

A new kind of CRISPR that destroys cells rather than gene editing them has shown potential for killing sick cells while ...